206 related articles for article (PubMed ID: 30157960)
1. Clinical epidemiology, risk factors and treatment outcomes of extended-spectrum beta-lactamase producing Enterobacteriaceae bacteremia among children in a Tertiary Care Hospital, Bangkok, Thailand.
Nivesvivat T; Piyaraj P; Thunyaharn S; Watanaveeradej V; Suwanpakdee D
BMC Res Notes; 2018 Aug; 11(1):624. PubMed ID: 30157960
[TBL] [Abstract][Full Text] [Related]
2. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
[TBL] [Abstract][Full Text] [Related]
4. Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.
Abera B; Kibret M; Mulu W
PLoS One; 2016; 11(11):e0166519. PubMed ID: 27846254
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
[TBL] [Abstract][Full Text] [Related]
6. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
7. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
[TBL] [Abstract][Full Text] [Related]
10. Emergence of extended-spectrum β-lactamase producing Enterobacter spp. in patients with bacteremia in a tertiary hospital in southern Brazil.
Nogueira Kda S; Paganini MC; Conte A; Cogo LL; Taborda de Messias Reason I; da Silva MJ; Dalla-Costa LM
Enferm Infecc Microbiol Clin; 2014 Feb; 32(2):87-92. PubMed ID: 23587705
[TBL] [Abstract][Full Text] [Related]
11. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
12. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
14. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study.
Peralta G; Lamelo M; Alvarez-García P; Velasco M; Delgado A; Horcajada JP; Montero M; Roiz MP; Fariñas MC; Alonso J; Martínez LM; Gutiérrez-Macías A; Alava JA; Rodríguez A; Fleites A; Navarro V; Sirvent E; Capdevila JA;
BMC Infect Dis; 2012 Oct; 12():245. PubMed ID: 23038999
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
[TBL] [Abstract][Full Text] [Related]
16. Extended spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural Ghana, 2007-2012.
Eibach D; Belmar Campos C; Krumkamp R; Al-Emran HM; Dekker D; Boahen KG; Kreuels B; Adu-Sarkodie Y; Aepfelbacher M; Park SE; Panzner U; Marks F; May J
Int J Med Microbiol; 2016 Jun; 306(4):249-54. PubMed ID: 27222489
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase.
Morfín-Otero R; Mendoza-Olazarán S; Silva-Sánchez J; Rodríguez-Noriega E; Laca-Díaz J; Tinoco-Carrillo P; Petersen L; López P; Reyna-Flores F; Alcantar-Curiel D; Garza-Ramos U; Garza-González E
Microb Drug Resist; 2013 Oct; 19(5):378-83. PubMed ID: 23725513
[TBL] [Abstract][Full Text] [Related]
19. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
Sethaphanich N; Santanirand P; Rattanasiri S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
Pediatr Int; 2016 May; 58(5):338-46. PubMed ID: 26513341
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
